摘要
目的探讨血脂康胶囊对急性冠脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)术后血脂及主要不良心血管事件(MACE)的影响。方法选取2015年6—12月在滁州市第一人民医院行PCI的ACS患者100例,随机分为对照组和观察组,每组50例。对照组患者PCI术后给予常规药物治疗,观察组患者PCI术后在常规药物治疗基础上给予血脂康胶囊;两组患者至少治疗180 d。比较两组不同ACS分型患者Gensini积分,入院当天、出院当天、出院后第90天和出院后第180天血脂指标,随访期间MACE发生情况。结果两组不同ACS分型患者Gensini积分比较,差异均无统计学意义(P>0.05)。入院当天和出院当天两组患者血清三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)及低密度脂蛋白胆固醇(LDL-C)水平比较,差异均无统计学意义(P>0.05);出院后第90天和第180天观察组患者血清TG、TC、LDL-C水平低于对照组,血清HDL-C水平高于对照组(P<0.05)。随访期间,对照组患者MACE发生率为72%,高于观察组的30%(P<0.05)。结论血脂康胶囊能有效改善ACS患者PCI术后血脂代谢并减少MACE的发生。
Objective To investigate the impact of xuezhikang capsule on blood lipid and major adverse cardiovascular events( MACE) in acute coronary syndrome patients undergoing PCI. Methods A total of 100 acute coronary syndrome patients undergoing PCI were selected in the First People’ s Hospital of Chuzhou from June to December 2015,and they were randomly divided into control group and observation group, each of 50 cases. After PCI, patients of control group received conventional medical treatment, while patients of observation group received extra xuezhikang capsule based on conventional medical treatment;both groups continuously treated for 180 days at least. Gensini score in patients with different types of acute coronary syndrome,blood lipid index at admission,at discharge,after 90 days and 180 days of discharge,and incidence of MACE during the follow-up were compared between the two groups. Results No statistically significant differences of Gensini score was found in patients with different types of acute coronary syndrome between the two groups( P > 0. 05). No statistically significant differences of serum level of TG,TC,HDL-C or LDL-C was found between the two groups at admission or at discharge( P > 0. 05);after 90 days and 180 days,serum levels of TG,TC and LDL-C of observation group were statistically significantly lower than those of control group,while serum HDL-C level of observation group was statistically significantly higher than that of control group,respectively( P < 0. 05). During the follow-up, the incidence of MACE of control group was 72%, was statistically significantly higher than that of observation group of 30%( P < 0. 05). Conclusion Xuezhikang capsule can effectively adjust the blood lipid metabolism of acute coronary syndrome patients undergoing PCI, is helpful to reduce the incidence of MACE.
作者
牛杰
黎敬锋
王超
王厚阳
李银
朱章进
徐晓飞
张德勤
孙阳
汪菲
NIU Jie;LI Jing-feng;WANG Chao;WANG Hou-yang;LI Yin;ZHU Zhang-jin;XU Xiao-fei;ZHANG De-qin;SUN Yang;WANG Fei(Department of Cardiology,the First People′s Hospital of Chuzhou,Chuzhou 239000,China)
出处
《实用心脑肺血管病杂志》
2016年第12期70-73,共4页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
急性冠脉综合征
血脂康胶囊
血脂
主要不良心血管事件
Acute coronary syndrome
Xuezhikang capsule
Blood lipid
Major adverse cardiovascular events
